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ABSTRACT: Phosphodiesterase 9 (PDE9) inhibitors have been studied as potential
therapeutics for treatment of diabetes and Alzheimer’s disease. Here we report a potent
PDE9 inhibitor 3r that has an IC50 of 0.6 nM and >150-fold selectivity over other PDEs. The
HepG2 cell-based assay shows that 3r inhibits the mRNA expression of phosphoenolpyruvate
carboxykinase and glucose 6-phosphatase. These activities of 3r, together with the reasonable
pharmacokinetic properties and no acute toxicity at 1200 mg/kg dosage, suggest its potential
as a hypoglycemic agent. The crystal structure of PDE9-3r reveals significantly different
conformation and hydrogen bonding pattern of 3r from those of previously published 28s.
Both 3r and 28s form a hydrogen bond with Tyr424, a unique PDE9 residue (except for
PDE8), but 3r shows an additional hydrogen bond with Ala452. This structure information
might be useful for design of PDE9 inhibitors.
■ INTRODUCTION
Diabetes mellitus (DM) is a group of metabolic diseases that
feature high blood sugar levels in patients. There are three main
types of DM: type I or insulin-dependent DM in which the
body fails to produce insulin; type II or insulin resistant DM in
which there is dysregulation of insulin production/secretion as
well as decreased sensitivity of peripheral tissues to insulin; and
gestational diabetes that is typically associated with pregnant
women.1 DM affects 26 million Americans or 8.3% population
in the United States (www.cdc.gov/diabetes/surveilance) and
has become a worldwide threat to public health. Thus, dis-
covery of hypoglycemic agents with strong potency and weak
side effect is highly desirable.
Targeting at the signaling pathway of cyclic guanosine mono-
phosphate (cGMP), which is a second messenger and plays
critical roles in many physiological processes, appears to be a
new promising direction to fight DM. An early study showed
that the platelet cGMP concentration and the NO production
were increased by insulin in dose-dependent manner.2 Later,
the NO/cGMP signaling pathway was shown to attenuate
vascular inflammation and insulin resistance3,4 and delay oocyte
aging in DM.5 Thus, regulation of cellular cGMP, which can be
achieved via inhibition of phosphodiesterases (PDEs), would
potentially be a strategy for treatment of DM. PDEs are a
superfamily of enzymes that hydrolyze cGMP and cAMP and
have been studied as drug targets for treatment of human
diseases.6−9 Twenty-one human PDE genes are classified into
11 families and encode >100 isoforms of proteins. PDE5, PDE6,
and PDE9 specifically recognize cGMP as their substrate, while
PDE4, PDE7, and PDE8 are cAMP-specific. The remaining
PDE families are capable of degrading both cGMP and
cAMP.6−9
The idea of targets at cGMP signaling pathway for treatment
of DM originated from an early study that the cGMP-inhibited
PDE (PDE3) played a critical role in the antilipolytic action of
insulin.10 Later, PDE3B was shown to mediate the inhibition
of lipolysis by proinsulin C-peptide in diabetic rat adipose
tissue11 and to play an important role in acquisition of brown
fat characteristics by white adipose tissue in male mice.12
In addition, PDE5 inhibitors enhanced muscle microvascular
blood flow and glucose uptake response to insulin13 and
improved dysfunction of metabolic and inflammatory processes
in diabetic nephropathy.14 Moreover, inhibition of PDE10A
has been recently shown to protect mice from diet-induced
obesity and insulin resistance.15 For the highest affinity of
cGMP with PDE9,7 several PDE9 inhibitors were patented for
the potential treatment of diabetes and cardiovascular diseases
in early years.16−20 After publication of the first PDE9 selective
inhibitor BAY73-6691,21 highly potent PDE9A inhibitors
such as PF-04447943,22 PF-4181366,23 and 28s24 have been
reported (Figure 1). However, interest in PDE9 inhibitors
has shifted to their applications to CNS diseases such as
Alzheimer’s disease.25−31 The most potent compound, PF-
04447943, completed its phase II clinical trial for the treatment
of mild Alzheimer’s disease in April 2013.
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Our initial effort on structure-based inhibitor design led to
discovery of compound 28s that uniquely forms a hydrogen
bond with Tyr424 and has high affinity with PDE9A (IC50 =
21 nM) and good selectivity over other PDEs.24 In this paper,
we report an improved compound 3r that has IC50 = 0.6 nM
against PDE9A and at least 150-fold selectivity over other PDEs.
The crystal structure of PDE9A-3r reveals significant differences
in conformation and hydrogen bonding pattern between 3r
from 28s. A cell-based assay shows that 3r inhibits the mRNA
expression of phosphoenolpyruvate carboxykinase (PEPCK)
and glucose 6-phosphatase (G-6-Pase), implying its potential as
a hypoglycemic agent.
■ RESULTS
Design of New PDE9A Inhibitors. We have previously
reported a potent PDE9 inhibitor 28s that has an IC50 of 21
nM against PDE9A and an 860-fold selectivity over PDE1B.24
This compound directly forms a hydrogen bond with Tyr424
that is unique for PDE9 and PDE8 (phenylalanine in other PDE
families) and may significantly contribute to selective binding
of 28s to PDE9 over other PDE families. However, since 28s
contains an L-Ala block (Figure 1) that is predicted to be
sensitive to stomach proteases, its in vivo stability would be a
potential problem. Thus, we chose the pyrazolopyrimidinone
ring of 28s as the scaffold and took the crystal structure of
PDE9-28s24 as the template to design new PDE9 inhibitors, in
hopes of improvement on binding affinity and in vivo stability.
Specifically, substitutions at the R1 and R3 positions and
enantiomers at the R2 position of 28s (Scheme 1) were
optimized to obtain stable and potent PDE9 inhibitors.
Structure−Activity Relationships. For the substitution
at the R1 position, the cyclopentyl group had better affinity
for PDE9A than the isopropyl, isobutyl, or chlorophenyl group,
as shown by the IC50 values of 3r (0.6 nM), 6r (1.0 nM), 7r
(17.6 nM), and 28r (6.4 nM, Table 1). For the R2 substitution,
the methyl group was better than both hydrogen (28r/28s ∼ 1,
3r/3s ∼ 2, 6r ∼ 5, Table 1) and the isobutyl group (3r/3s ∼ 4r).
The replacement of the methoxyl group with fluorine at the R3
position produced similar affinity of the inhibitors against
PDE9 (3r ∼ 8r). Among the studied compounds, 3r showed
the best potency with an IC50 of 0.6 nM against the PDE9A
catalytic domain (Table 1), which is 35-fold better than 28s.
This affinity improvement appears to be dominantly contributed
by the replacement of chlorophenyl ring of 28s with cyclopentyl
group of 3r.
The (R)-enantiomers of 28r and 3r showed 3- to 5-fold
better affinity with PDE9 than their (S)-enantiomeric counter-
parts (Table 1). This result agrees with the early report that the
(R)-enantiomer of BAY73-6691 has about 4-fold better affinity
than its (S)-enantiomer.32 Explanation of this consistency is not
clear, but it might mean that the binding pocket of PDE9 has
a special shape for better fitting of the (R)-enantiomers than
the (S)-enantiomers.
To investigate (R)-/(S)-enantiomers’ impact on selectivity,
inhibitions of both (R)-/(S)-enantiomers of 3 and 28 were
assayed against other PDE families (Table 2). Overall, all four
compounds of 3 and 28 predominantly inhibit PDE9 with
Figure 1. Chemical structures of PDE9 inhibitors. The symbol ∗ marks the chiral carbon that makes two enantiomers.
Scheme 1. Synthesis of PDE9A Inhibitorsa
aSymbol ∗ marks the chiral carbon that makes two enantiomers.
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moderate selectivity over PDE5A1 (22- to 150-fold, Table 2).
(R)-Enantiomers of 3r and 28r showed better affinity than their
(S)-enantiomers against PDE1B2, PDE5A1, PDE7A1, and
PDE10A2, but no consistent trend was observed for PDE4D2
(Table 2). Both enantiomers of 3 and 28 barely inhibit PDE8
(IC50 of ∼100 μM, Table 2), which also contains a tyrosine at
the corresponding position of Tyr424 of PDE9A2, implying
that the inhibitory selectivity is jointly determined by multiple
residues at the active sites of the PDE families.
We further tested the impact of the substitutions and
enantiomers on the plasma protein binding (PPB) to see how
much of the inhibitors are freely available for their binding to
PDE9. The PPB assay was conducted using human plasma for
compounds 3r, 3s, and 28s at concentrations of 1 and 5 μM
(Supporting Information S1). In short, these compounds
strongly interact with plasma proteins, as shown by the bound
percentage of >94.3%. The enantiomers and substitutions at
the R1 position do not significantly impact the binding of these
compounds to plasma proteins. Although a large percentile for
plasma protein binding implies reduced availability of inhibitors
for their targets,34 remaining free 3r in blood plasma might be
sufficient for blocking the PDE9-cGMP signaling because of its
high affinity with PDE9 (IC50 of 0.6 nM).
Binding of 3r to PDE9. The X-ray structure of PDE9-3r,
which was prepared by soaking of the PDE9-IBMX crystal in
2 mM 3r, shows definite 3r binding to the active site of
PDE9A2 (Figure 2). The electron density in (2Fo − Fc) and
(Fo − Fc) maps clearly revealed the unique conformation of 3r.
The pyrazolopyrimidinone ring of 3r forms two hydrogen
Table 1. Chemical Structures of Inhibitors and Their
Affinities (IC50) with PDE9A2 (181−506)
a
aFootnotes: *28s from our previous report.24 #The predicted Ki was
calculated with equation IC50 = Ki(1 + [S]/KM), where [S] = 20 nM
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bonds with invariant Gln453 and aromatic π-stack against
Phe456, which are two characteristic interactions of inhibitors
with various PDE families,33 in addition to the hydrophobic
contacts with Leu420 and Ala452. The cyclopentyl ring of 3r
orients toward the metal binding pocket and closely contacts
Met365 and Tyr424. The tail of 3r (N-(4-methoxyphenyl)-2-
(methylamino)propanamide) forms two hydrogen bonds, res-
pectively, with the side chain of Tyr424 and the carbonyl oxygen
of Ala452 (Figure 2), in addition to the hydrophobic interac-
tions with Met365, Leu420, Phe441, Ala452, and Phe456.
Inhibitor 3r has a binding pattern overall similar to that of
28s (Figure 3), as seen from the superimposable pyrazolopyr-
imidinone rings and similar location of their remaining groups.
However, the tails of 3r and 28s show significantly different
conformations and interactions (Figure 3), although they have
the similar chemical components and occupy the same locations.
The replacement of the L-Ala block of 28s by a D-Ala unit of 3r
causes significant changes of hydrogen-bonding pattern. Tyr424
forms a hydrogen bond with the amide oxygen of L-Ala of 28s in
the structure of PDE9-28s24 but switches to the nitrogen
adjacent to D-Ala of 3r (Figure 3A). Interestingly, the nitrogen
atom of D-Ala of 3r forms a hydrogen bond (2.9 Å) with the
carbonyl oxygen of Ala452, in contrast to the very weak contact
(4.0 Å) in the PDE9-28s structure. This difference in hydrogen
bond pattern might explain the 35-fold better affinity of 3r
than 28s.
Significant Improvement of the in Vivo Properties of
3r over 28s. A preliminary pharmacokinetic analysis revealed
that 3r has Cmax of 217 ng/mL, bioavailability of 9.8%, and T1/2
of 1.7 h in the oral administration mode (Table 3). These
parameters show a significant improvement over these of 28s
(Cmax of 16 ng/mL, T1/2 of 0.3 h, and bioavailability of 1.3%).
The pharmacokinetic parameters of 3r from the intravenous
administration, such as C0 = 24 mg/L and T1/2 =5.3 h (Table 3),
appear to be promising, but further studies are required for
usability of 3r in intravenous administration mode. On the other
hand, 8r shows reasonable pharmacokinetic properties of 18%
bioavailability and T1/2 of 4.1 h in the oral administration mode
(Table 3).
To further characterize properties of the compounds, solubility
of 3r, 3s, and 28s was measured in simulated gastric/intestinal
fluids. All the three compounds were more soluble in the
simulated intestinal fluid (31, 31, and 13 μg/mL at pH 6.8 for 3r,
3s, and 28s) than in the simulated gastric fluid (26, 23, and
8 μg/mL at pH 1.4, Table 4). Comparable solubility of 3r and 3s
in the simulated gastric and intestinal fluids implies no strong
effect of the chirality on the solubility. However, the replacement
of the chloral-phenyl group of 28s by the cyclic pentanyl ring
of 3r (Figure 1), which is the only chemical difference between
3r/3s and 28s, appears to significantly contribute to the
solubility.
The solubility data imply that the moderate 9.8% bioavaila-
bility of 3r may be due to its metabolic instability. Thus, we test
the 3r stability in the mouse liver microsomes. The results
showed that 3r was not very stable in the mouse liver micro-
some, as shown by T1/2 of 23 min and Eh of 73% (Table 5).
However, 3r is significantly better than the positive control
Figure 3. Comparison on binding of several PDE9 inhibitors. (A)
Superposition between the crystal structures of PDE9-3r (yellow
sticks) and PDE9-28s (cyan). PDE9 is presented in the surface mode.
(B) Superposition between the crystal structures of PDE9-3r (cyan
and yellow sticks) and PDE9-(R)-BAY73-6691 (salmon and green
sticks).
Table 3. Pharmacokinetic Profile of PDE9A Inhibitors 3r and 8r in Mice/Ratsa
route iv CL (L h−1 kg−1) Vss (L/kg) MRT(0−∞) (h) AUC0−t (mg·h/L) AUC0−∞ (mg·h/L) C0 (μg/L) T1/2 (h) Tmax (h)
3r 1.43 ± 0.23 1.53 ± 0.15 1.08 ± 0.08 3529 ± 575 3550 ± 590 24535 ± 7525 5.34 ± 1.43
8r 1.78 ± 0.18 2.58 ± 0.07 0.59 ± 0.13 2821 ± 268 2825 ± 270 19085 ± 428 1.01 ± 0.09
route po CL (L h−1 kg−1) Vss (L/kg) MRT(0−∞) (h) AUC0−t (mg·h/L) AUC0−∞ (mg·h/L) Cmax (μg/L) T1/2 (h) Tmax (h) F (%)
3r 14.6 ± 3.5 35.0 ± 7.9 2.65 ± 0.82 346 ± 111 360 ± 101 217 ± 30 1.67 ± 0.04 0.58 ± 0.38 9.8 ± 3.1
8r 3.94 ± 1.11 463 ± 153 520 ± 213 135 ± 55 4.08 ± 1.00 1.00 ± 0.87 18 ± 7
aDose: 5 mg/kg. po = oral administration. iv = intravenous administration.
Table 4. Solubility Comparisons of PDE9 Inhibitors in
Simulated Gastric/Intestinal Fluids
solubility ± SD (μg/mL, N = 4)
simulated fluids 3r 3s 28s
gastric fluid (pH 1.4) 26 ± 7 23 ± 5 8 ± 2
intestinal fluid (pH 6.8) 31 ± 4 31 ± 8 13 ± 3
Figure 2. Binding of 3r to PDE9A. (A) Surface presentation of the 3r
binding to the active site pocket of PDE9A2. Atoms of carbon,
nitrogen, and oxygen of PDE9A are presented in colors of white, blue,
and red, respectively. Inhibitor 3r is shown as yellow sticks. Dotted
lines represent hydrogen bonds. (B) Ribbon model of the 3r binding.
The blue mesh is the electron density of the difference (Fo − Fc) map
that was calculated from the structure with omission of 3r and
contoured at 3σ.
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compounds of testosterone and propranolol, which have T1/2
of ∼2 min and Eh of ∼97% (Table 5).
Inhibitor 3r Does Not Show Acute Toxicity. Compound
3r was evaluated for acute toxicity. Twenty-four mice were
randomly divided into three groups and given in single oral
doses of 0, 600, or 1200 mg/kg 3r on the first day. The animals
treated with 3r did not show any poisoned symptoms and
mortality immediately or during the post-treatment period
of 2 weeks. In addition, no abnormal behaviors and significant
changes of water/food consumption and body weight were
observed during the period of the experiments. Therefore, 3r
was well tolerated up to a dose of 1200 mg/kg and has no acute
toxicity.
Inhibition on mRNA Expression of PEPCK and G-6-
Pase in HepG2 Cell by 3r. Upon stimulation by 8-Br-cAMP/
dexamethasone, the mRNA expression of two key hepatic
gluconeogenic genes of the HepG2 cell, PEPCK and G-6-Pase,
was enhanced respectively by 233% and 194% relative to the
basal level of the mRNA expression (Figure 4). As a positive
control, 300 nM insulin reduced the mRNA expression of
PEPCK and G-6-Pase to the basal level in HepG2 cell in the
presence of stimulation of cAMP/dexamethasone. As shown in
Figure 4, 3r at 10 nM sufficiently reduced the 8-Br-cAMP/
dexamethasone-induced expression of PEPCK and G-6-Pase
back to the basal level in HepG2 cells, implying that our
inhibitor 3r is a potential hypoglucemic agent.
■ DISCUSSION
Hints for Improvement of PDE9 Inhibitors. Compound
28s effectively inhibits PDE9 at enzymatic level, but its in vivo
stability needs to be improved. Although the cause of instability
is not clear, three weak chemical links in 28s are possibly the
candidates: the amide bond of the L-Ala unit, the methoxyl
group, and the N-link between nitrogen and pyrazolopyr-
imidinone (Figure 1). The L-Ala unit appears to be mostly
unstable and would be easily hydrolyzed by stomach proteases.
Because D-amino acids are in general more stable than L-amino
acids in stomach, the replacement of L-Ala with D-Ala may be a
major factor for the prolonged T1/2 values (0.85, 1.7, and 4.1 h for
28s, 3r, and 8r in the oral administration mode and 0.32, 5.34,
and 1.01 h for 28s, 3r, and 8r in the intravenous administration
mode, Table 3 and unpublished data for 28s). The longer T1/2
value of 8r (4.1 h) than 3r (1.7 h) in the po mode might imply
slower absorption of 8r by intestinal. However, the shorter T1/2
value of 8r (∼1 h) than 3r (∼5 h) in the iv mode might imply
that 8r is unstable and decomposable in liver. In short, the
explanation of the data of metabolic stability and bioavailability
could not be firmly concluded, and further improvement of the
compounds is desirable.
The crystal structure of PDE9-3r shows that the methyl side
chain of D-Ala of 3r points toward a hydrophobic subpocket that
is composed of Leu420, Leu421, Phe441, Ala452, and Val457
(Figure 3A). Thus, a tentative modification on the inhibitors
might be an extension of the side chain of D-Ala with hydrophobic
groups such as propanyl chain to fill the hydrophobic pocket
for improvement of affinity and selectivity. This extension might
also serve as a stereo-obstacle to protect the N-link and amide
bond of the compounds from decomposition in vivo by live
enzymes. Following this assumption, compound 4r that contains
D-isoleucine in the place of D-Ala of 3r was synthesized.
Table 5. Metabolic Stability of 3r in Liver Microsomes of CD-1 Mousea
compd k T1/2 (min) Clint (mL min
−1 mg−1) Clapp (mL min
−1 kg−1) Clh (mL min
−1 kg−1) Eh (%)
testosterone 0.34604 2.0 0.6921 2725.1 87.1 96.8
propranolol 0.45726 1.5 0.9145 3600.9 87.8 97.6
warfarin 0.00393 176.5 0.0079 30.9 23.0 25.6
3r 0.03102 22.3 0.0620 244.3 65.8 73.1
aTestosterone, propranolol, and warfarin are the positive controls.
Figure 4. Inhibition of the mRNA expression in HepG2 cell line by PDE9 inhibitor 3r: (A) G-6-Pase mRNA expression; (B) PEPCK mRNA
expression.
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Unfortunately, the enzymatic assay shows slightly reduced
potency of 4r (IC50 = 8.1 nM) in comparison to 0.6 nM of 3r.
A molecular docking suggests that 4r binds to PDE9 in a similar
pattern to 3r with slight position shift of the whole molecule, but
the side chain of D-Leu did not penetrate into the small
hydrophobic pocket. It remains to be elucidated if D-Leu could
serve as a stereo-obstacle so as to improve the in vivo stability and
if other replacements such as a straight propanyl group could
penetrate the hydrophobic pocket and thus improve the affinity
and stability.
■ CONCLUSION
Our structure-based design led to discovery of a PDE9 selective
inhibitor 3r that is capable of inhibiting the mRNA expression
of PEPCK and F-6-Pase and thus a potential hypoglucemic
agent.
■ EXPERIMENTAL SECTION
Molecular Docking. Hydrogen atoms and charges were added
to the PDE9A structure (PDB entry code 4GH6)24 using the
CHARMM force field and the Momany−Rone partial charge method
as implemented in Accelrys Discovery Studio 2.5.5.35 All ionizable
residues in the systems were set to their protonation states at a neutral
pH. The zinc and magnesium ions were assigned with a charge of +2.
Ligand 28s was used to define the active site of PDE9A and test
docking by the CDOCKER36 and LigandFit37 protocols embedded in
Accelrys Discovery Studio 2.5.5. The radius of the input sphere was set
as 10 Å from the center of the binding site, and the rest of the docking
parameters used the default values. Fifty random conformations were
generated and optimized for each ligand. The output poses from
docking were evaluated by the score of the program and also by visual
inspection.
Syntheses. 1H NMR and 13C NMR spectra were recorded at room
temperature on a Mercury-Plus 300 instrument or a Bruker AVANCE
III 400 instrument with TMS as an internal reference. LC/MS was
run on a LCMS-2010A. Thin-layer chromatography was performed
on precoated silica gel F-254 plates (0.25 mm, E. Merck). Element
analyses were carried out with a Vario EL series analyzer. Melting
points were determined on a WRS-1B digital melting point apparatus
and were not calibrated. IR spectra were recorded on a Thermo
330 FT-IR. All starting materials and reagents were purchased from
commercial suppliers and used directly without further purification.
The syntheses of M0 and 28s were previously reported.24 Syntheses
of intermediates M1−M3 and compounds 28r and 1−8r are shortly
described as follows. The pyrazolopyrimidinones (M1−M3) and
2-amino-N-phenylacetamide derivatives with R2 and R3 substitutions
(Scheme 1) were synthesized by the similar protocols in literature.24,38
Briefly, to a 10 mL of sealed vial were added i-PrOH (3 mL),
pyrazolopyrimidinones (0.5 mmol), 2-amino-N-phenylacetamide
derivatives (1.0 mmol), and Et3N (1.5 mmol). The reaction mixture
was stirred in an oil bath preheated to 90 °C. After completion of the
reaction as indicated by TLC, the reaction mixture was cooled to room
temperature and concentrated in vacuo. The residue was purified by
flash column chromatography on silica gel (eluted with DCM/MeOH =
25:1) to provide the targeted compounds. The following are the
characterization of the compounds. The data of elemental analysis for all
the new compounds are provided in the Supporting Information S2.
6-Chloro-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-ol (M1).
White solid, yield, 80%. Mp: 216−217 °C. MS (ESI−), m/z: 211
([M − H]−). 1H NMR (400 MHz, CDCl3) δ (ppm) 8.12 (s, 1H), 5.01
(hept, J = 6.7 Hz, 1H), 1.54 (d, J = 6.7 Hz, 6H). 13C NMR (101 MHz,
CDCl3) δ (ppm) 159.9, 150.7, 145.7, 1345.0, 104.1, 49.8, 22.0. IR
(KBr, cm−1): 3434, 3085, 2976, 2877, 1715, 1674, 1585, 1526, 1442,
1268, 1119, 957, 884, 778, 686, 557, 467. Purity >99.5%.
6-Chloro-1-cyclopentyl-1H-pyrazolo[3,4-d]pyrimidin-4-ol (M2).
White solid, yield, 82%. Mp: 228−230 °C. MS (ESI−), m/z: 237
([M − H]−). 1H NMR (400 MHz, CDCl3) δ (ppm) 8.10 (s, 1H),
5.15 (p, J = 7.5 Hz, 1H), 2.20−2.04 (m, 4H), 2.02−1.91 (m, 2H), 1.72
(ddd, J = 11.2, 7.8, 3.2 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ
(ppm) 159.9, 151.4, 145.8, 135.1, 104.3, 58.4, 32.6, 24.8. IR (KBr,
cm−1): 3429, 2951, 2871, 1713, 1674, 1583, 1529, 1444, 1273, 1227,
1089, 957, 883, 778, 675, 553. Purity >99.5%.
6-Chloro-1-isobutyl-1H-pyrazolo[3,4-d]pyrimidin-4-ol (M3).
White solid, yield, 70%. Mp: 146−148 °C. MS (ESI−), m/z: 225
([M − H]−). 1H NMR (400 MHz, CDCl3) δ (ppm) 12.45 (brs, 1H),
8.11 (s, 1H), 4.13 (d, J = 7.4 Hz, 2H), 2.33 (dp, J = 13.8, 6.9 Hz, 1H),
0.92 (d, J = 6.7 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ (ppm)
159.9, 152.0, 146.0, 135.1, 103.9, 54.9, 29.0, 19.8. IR (KBr, cm−1):
3424, 3094, 3070, 3013, 2958, 2873, 1714, 1673, 1582, 1534, 1448,
1393, 1273, 1230, 1204, 1171, 1157, 1076, 1033, 957, 886, 778, 743,
672, 547. Purity >99.5%.
(R)-2-((1-(2-Chlorophenyl)-4-hydroxy-1H-pyrazolo[3,4-d]-
pyrimidin-6-yl)amino)-N-(4-methoxyphenyl)propanamide (28r).
White solid, yield, 60%. Mp: 155−156 °C. MS (ESI−), m/z: 437
([M − H]−). 1H NMR (300 MHz, CDCl3) δ (ppm) 10.59 (brs, 1H),
8.17 (brs, 1H), 8.12 (s, 1H), 7.53−7.45 (m, 2H), 7.41−7.29 (m, 2H),
7.09 (d, J = 8.9 Hz, 2H), 7.00 (d, J = 5.0 Hz, 1H), 6.77 (d, J = 8.9 Hz,
2H), 4.50 (p, J = 6.8 Hz, 1H), 3.76 (s, 3H), 1.49 (d, J = 6.9 Hz, 3H).
13C NMR (75 MHz, CDCl3) δ (ppm) 170.9, 159.6, 156.8, 155.4,
153.1, 137.0, 135.5, 131.9, 130.6, 130.4, 129.7, 127.6, 122.1, 114.2,
100.9, 55.8, 51.7, 17.9. IR (pure, cm−1): 3292, 3072, 2933, 2835,
1678, 1602, 1509, 1548, 1509, 1490, 1237, 1117, 1033, 971, 828, 672.
Purity >99.5%.
2-((1-(2-Chlorophenyl)-4-hydroxy-1H-pyrazolo[3,4-d]pyrimidin-
6-yl)amino)-N-(4-methoxyphenyl)acetamide (1). White solid, yield,
50%. Mp 213-215 °C. MS (ESI−), m/z: 423 ([M − H]−). 1H NMR
(400 MHz, DMSO-d6) δ (ppm) 10.87 (brs, 1H), 9.93 (s, 1H), 8.05 (s,
1H), 7.66−7.62 (m, 1H), 7.55−7.49 (m, 2H), 7.47−7.38 (m, 3H),
7.01 (brs, 1H), 6.92−6.85 (m, 2H), 3.98 (d, J = 4.7 Hz, 2H), 3.72 (s,
3H). 13C NMR (101 MHz, DMSO-d6) δ (ppm) 166.9, 158.1, 156.0,
155.8, 154.3, 136.7, 135.9, 132.3, 131.4, 131.0, 130.7, 130.3, 128.3,
121.2, 114.4, 100.5, 55.6, 44.5. IR (pure, cm−1): 3268, 3101, 2837,
1678, 1613, 1543, 1511, 1488, 1445, 1413, 1393, 1300, 1242, 1061,
1030, 965, 828, 763, 673, 639. Purity >99.5%.
2-((1-Cyclopentyl-4-hydroxy-1H-pyrazolo[3,4-d]pyrimidin-6-yl)-
amino)-N-(4-methoxyphenyl)acetamide (2). White solid, yield,
50%. Mp:220−221 °C. MS (ESI−), m/z: 381 ([M − H]−). 1H
NMR (400 MHz, DMSO-d6) δ (ppm) 10.02 (s, 1H), 7.76 (s, 1H),
7.50 (d, J = 9.0 Hz, 2H), 6.92−6.84 (m, 3H), 4.89 (p, J = 7.4 Hz, 1H),
4.13 (d, J = 5.1 Hz, 2H), 3.72 (s, 3H), 1.99−1.87 (m, 4H), 1.87−1.75
(m, 2H), 1.65−1.52 (m, 2H). 13C NMR (101 MHz, DMSO-d6) δ
(ppm) 167.4, 158.2, 155.8, 153.9, 153.6, 134.3, 132.4, 121.2, 114.4,
100.3, 57.2, 55.6, 44.7, 32.0, 24.6. IR (pure, cm−1): 3457, 3274, 3068,
2967, 1683, 1665, 1608, 1528, 1514, 1314, 1245, 1171, 1052, 1032,
823, 776, 726, 707, 628. Purity >99.5%.
(R)-2-((1-Cyclopentyl-4-hydroxy-1H-pyrazolo[3,4-d]pyrimidin-6-
yl)amino)-N-(4-methoxyphenyl)propanamide (3r). White solid,
yield, 23%. Mp: 135−136 °C. MS (ESI−), m/z: 395 ([M − H]−).
1H NMR (400 MHz, CDCl3) δ (ppm) 7.74 (s, 1H), 7.47 (d, J =
9.0 Hz, 2H), 6.86 (d, J = 9.1 Hz, 2H), 4.86−4.77 (m, 1H), 4.46 (q, J =
6.9 Hz, 1H), 3.68 (s, 3H), 1.92 (dd, J = 8.4, 5.0 Hz, 2H), 1.75 (t, J =
7.2 Hz, 4H), 1.62−1.45 (m, 2H), 1.40 (d, J = 7.0 Hz, 3H). 13C NMR
(101 MHz, CDCl3) δ (ppm) 174.9, 161.9, 159.4, 157.3, 156.1, 137.9,
135.7, 124.8, 117.8, 103.8, 61.0, 59.2, 54.6, 35.4, 35.2, 28.0, 28.0, 22.1.
IR (pure, cm−1): 3299, 2952, 2871, 1675, 1605, 1547, 1510, 1444,
1238, 1034, 827, 775. Purity >99.5%.
(S)-2-((1-Cyclopentyl-4-hydroxy-1H-pyrazolo[3,4-d]pyrimidin-6-
yl)amino)-N-(4-methoxyphenyl)propanamide (3s). White solid,
yield, 34%. Mp:133−134 °C. MS (ESI−), m/z: 395 ([M − H]−).
1H NMR (400 MHz, DMSO-d6) δ (ppm) 10.44 (s, 1H), 10.08 (s,
1H), 7.75 (s, 1H), 7.55−7.49 (m, 2H), 6.93−6.86 (m, 3H), 4.88 (p,
J = 7.3 Hz, 1H), 4.56 (p, J = 6.8 Hz, 1H), 3.72 (s, 3H), 2.02−1.92 (m,
2H), 1.88−1.77 (m, 4H), 1.63−1.51 (m, 2H), 1.44 (d, J = 6.9 Hz,
3H). 13C NMR (101 MHz, DMSO-d6) δ (ppm) 171.1, 158.1, 155.8,
153.8, 152.8, 134.3, 132.4, 121.3, 114.3, 100.4, 57.3, 55.6, 50.9, 32.0,
31.9, 24.6, 24.5, 19.1. IR (pure, cm−1): 3301, 2959, 1675, 1605, 1548,
1510, 1448, 1238, 1035, 827, 775. Purity >99.5%.
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(R)-2-((1-Cyclopentyl-4-oxo-4,5-dihydro-1H-pyrazolo[3,4-d]-
pyrimidin-6-yl)amino)-N-(4-methoxyphenyl)-4-methylpentanamide
(4r). White solid, yield, 52%. Mp: 118−120 °C. MS (ESI−), m/z: 439
([M + H]+). 1H NMR (400 MHz, CDCl3) δ (ppm) 10.67 (s, 1H),
8.65 (s, 1H), 7.77 (s, 1H), 7.39 (d, J = 6.3 Hz, 2H), 6.77 (d, J = 6.8
Hz, 2H), 4.90 (s, 1H), 4.64 (s, 1H), 3.71 (s, 3H), 2.12−1.48 (m,
11H), 0.91 (s, 6H). 13C NMR (101 MHz, CDCl3) δ (ppm) 171.0,
160.0, 156.7, 153.5, 152.4, 134.4, 130.4, 122.0, 114.1, 100.1, 57.5, 55.4,
54.4, 41.2, 32.0, 24.9, 24.6, 22.9, 22.0. IR (KBr, cm−1): 3328, 2955,
1679, 1609, 1551, 1511, 1448, 1242, 1170, 1037, 882, 778, 707. Purity
>99.5%.
2-((4-Hydroxy-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-6-yl)-
amino)-N-(4-methoxyphenyl)acetamide (5). White solid, yield, 35%.
Mp: 178−179 °C. MS (ESI−), m/z: 355 ([M − H]−). 1H NMR
(400 MHz, DMSO-d6) δ (ppm) 10.72 (s, 1H), 10.02 (s, 1H), 7.75 (s,
1H), 7.49 (d, J = 9.0 Hz, 2H), 6.88 m, 3H), 4.78−4.67 (m, 1H), 4.14
(d, J = 5.1 Hz, 2H), 3.72 (s, 3H), 1.36 (d, J = 6.7 Hz, 6H). 13C NMR
(101 MHz, DMSO-d6) δ (ppm) 167.4, 158.2, 155.8, 153.6, 153.4,
134.2, 132.3, 121.3, 114.4, 100.4, 55.6, 48.4, 44.7, 22.0. IR (pure,
cm−1): 3308, 2979, 1675, 1608, 1542, 1510, 1497, 1444, 1414, 1246,
1034, 826, 778. Purity >99.5%.
(R)-2-((4-Hydroxy-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-6-yl)-
amino)-N-(4-methoxyphenyl)propanamide (6r). White solid, yield,
54%. Mp: 131−132 °C. MS (ESI−), m/z: 369 ([M − H]−). 1H NMR
(400 MHz, CDCl3) δ (ppm) 7.87 (s, 1H), 7.41 (d, J = 8.9 Hz, 2H),
6.83 (d, J = 8.9 Hz, 2H), 4.85−4.78 (m, 2H), 4.70−4.62 (m, 1H), 3.77
(s, 3H), 1.58 (d, J = 7.0 Hz, 3H), 1.45 (dd, J = 14.9, 6.7 Hz, 6H).
13C NMR (101 MHz, CDCl3) δ (ppm) 171.0, 159.9, 156.8, 153.0,
152.0, 134.5, 130.3, 121.9, 114.2, 100.3, 55.4, 51.5, 48.9, 21.8, 17.8.
IR (pure, cm−1): 3284, 2980, 2937, 1678, 1605, 1546, 1510, 1443,
1239, 1135, 1033, 828, 776. Purity >99.5%.
(R)-2-((4-Hydroxy-1-isobutyl-1H-pyrazolo[3,4-d]pyrimidin-6-yl)-
amino)-N-(4-methoxyphenyl)propanamide (7r). White solid, yield,
40%. Mp: 146−147 °C. MS (ESI−), m/z: 383 ([M − H]−). 1H NMR
(400 MHz, CDCl3) δ (ppm) 7.75 (s, 1H), 7.51−7.44 (m, 2H), 6.88−
6.82 (m, 2H), 4.47 (q, J = 6.9 Hz, 1H), 3.92−3.74 (m, 2H), 3.68 (s,
3H), 2.05 (dp, J = 13.6, 6.8 Hz, 1H), 1.40 (d, J = 7.0 Hz, 3H), 0.69 (d,
J = 6.7 Hz, 3H), 0.63 (d, J = 6.7 Hz, 3H). 13C NMR (101 MHz,
CDCl3) δ (ppm) 174.9, 162.0, 159.4, 158.1, 156.3, 138.1, 135.8, 124.8,
117.8, 103.4, 59.2, 57.2, 54.5, 32.3, 23.6, 23.5, 22.2. IR (pure, cm−1):
3305, 2960, 1678, 1608, 1548, 1510, 1448, 1414, 1240, 1171, 1033,
827, 776, 758, 726, 698, 640. Purity >99.5%.
(R)-2-((1-Cyclopentyl-4-oxo-4,5-dihydro-1H-pyrazolo[3,4-d]-
pyrimidin-6-yl)amino)-N-(4-fluorophenyl)propanamide (8r). White
solid, yield, 57%. Mp: 223−224 °C. MS (ESI−), m/z: 385 ([M + H]+).
1H NMR (400 MHz, DMSO-d6) δ (ppm) 10.43 (s, 1H), 10.29 (s,
1H), 7.75 (s, 1H), 7.69−7.55 (m, 2H), 7.16 (t, J = 8.9 Hz, 2H), 6.92
(d, J = 6.5 Hz, 1H), 4.92−4.79 (m, 1H), 4.54 (p, J = 6.7 Hz, 1H),
2.02−1.90 (m, 2H), 1.80 (t, J = 7.6 Hz, 4H), 1.64−1.48 (m, 2H), 1.44
(d, J = 6.9 Hz, 3H). 13C NMR (101 MHz, DMSO-d6) δ (ppm) 171.5,
158.0, 157.3, 153.7, 152.7, 135.7, 134.3, 121.4, 121.3, 115.8, 115.6,
100.3, 57.3, 51.0, 31.9, 31.8, 24.5, 24.4, 18.9. IR (pure, cm−1): 3425,
2961, 2872, 2027, 1677, 1611, 1554, 1510, 1448, 1409, 1297, 1264,
1218, 1153, 1098, 1077, 1043, 1004, 952, 909, 833, 779, 690, 616, 571.
Purity >99.5%.
Protein Expression and Purification. The PDE9A2 catalytic
domain (residues 181−506) was subcloned to vector pET15b and
purified according to the protocols described previously.39,40 Briefly,
the pET15-PDE9 plasmid was transferred into E. coli strain BL21
(Codonplus, Stratagene) for overexpression. When the E. coli cell was
grown in LB medium at 37 °C to absorption A600 = 0.7, 0.1 mM
isopropyl β-D-thiogalactopyranoside was added to induce the expression
at 15 °C overnight. Recombinant PDE9A2 protein was purified by
column chromatography of Ni-NTA, Q-Sepharose, and Superdex-200
(GE Healthcare). A typical batch of purification yielded 20−60 mg of
PDE9A2 from a liter cell culture. The PDE9A2 proteins had purity
greater than 95% as judged by mini SDS−PAGE, in which no visible
bands for other proteins were visible when >20 μg of PDE protein was
loaded into the GEL. The catalytic domains of PDE5A1 (535−860),
PDE4D2 (86−413), PDE7A1 (130−482), PDE8A2 (480−820), and
PDE10A2 (448−789) were purified by the published protocols.41−45
PDE1B (10−516) was expressed and purified using a similar protocol.
Enzymatic Assay. The enzymatic activities of PDEs were assayed
by using 3H-cGMP or 3H-cAMP as the substrate. The assay buffer was
50 mM Tris-HCl, pH 8.0, 10 mM MgCl2 or 4 mM MnCl2, 1 mM
DTT, and 20 nM 3H-cGMP or 3H-cAMP (20 000−30 000 cpm/assay,
GE Healthcare). The reaction was carried out at room temperature for
15 min and then terminated by addition of 0.2 M ZnSO4. The reaction
product 3H-GMP was precipitated by adding 0.2 N Ba(OH)2, while
the unreacted 3H-cGMP remained in the supernatant. Radioactivity in
the supernatant was measured in 2.5 mL of Ultima Gold liquid scintilla-
tion cocktails by a liquid scintillation counter. For the measurement of
IC50, at least eight concentrations of inhibitors were used in the
presence of suitable substrates. The enzymes used in the assay had
about final 50−200 ng/mL concentration and hydrolyzed up to 70% of
the substrates. Each measurement was repeated three times. The IC50
values were calculated by nonlinear regression.
Crystallization and Structure Determination. The crystals of
PDE9A2 were grown by using hanging drop vapor diffusion method.
The PDE9A2 (181−506) (8−10 mg/mL) in a buffer of 50 mM
NaCl, 20 mM Tris-HCl, pH 7.5, 1 mM β-mercaptoethanol, and 1 mM
EDTA was mixed with 2 mM IBMX overnight before setting-up of
crystallization against the well buffer of 0.1 M HEPES (pH 7.5), 3.0 M
sodium formate at 4 °C. Crystals of the PDE9-3r complex were
prepared by soaking the PDE9-IBMX cocrystals in the crystallization
buffer plus 2 mM 3r at 25 °C for 3 days. The crystals were flash-frozen
in liquid nitrogen by using the well buffer plus 20% glycerol as the
cryosolvent. X-ray diffraction data were collected at λ = 1.075 on
beamline X29 in Brookhaven National Laboratory and processed by
HKL 2000 (Table 6).46 The structure of the PDE9-3r complex was
solved by the molecular replacement, using the PDE9A2 catalytic
domain of the PDE9-IBMX complex as the initial model.39 The resulting
model was rebuilt by program O47 and refined by CNS (Table 6).48
Cell-Based Assay for Inhibition on the mRNA Expression of
PEPCK and G-6-Pase. The cell-based assay was performed following
the protocols described in literature.49 HepG2 cells were incubated in




unit cell: a, c (Å) 103.6, 268.7
resolution (Å) 2.0
total measurements 953,981
unique reflections 91 112
completeness (%) 91.5 (71.8)a







reflections 91 068 (9098)b
rms deviation for
bond length (Å) 0.006
bond angle (deg) 1.2
average B-factor (Å2)
protein 36.8 (5306)c




aThe numbers in parentheses are for the highest resolution shell. bThe
number of reflections omitted for calculation of Rfree.
cThe number of
atoms in the crystallographic asymmetric unit.
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serum at 37 °C in 5% CO2 overnight and then grown in the absence of
serum for starvation overnight. After starvation, 1 μM dexamethasone
(20 mM stock in 100% DMSO) and 0.5 mM 8-Br-cAMP (100 mM
stock in water) were added and further incubated for 30 h. Various
concentrations of PDE9 inhibitor 3r were then added into the culture
medium and incubated for 12 h. The mRNAs were extracted from the
treated HepG2 cell with Ultrapure RNA kit. The genes of G-6-Pase
and PEPCK were instantly synthesized by addition of 100 ng of cDNA
and detected by qPCR.
Pharmacokinetics Analysis. Pharmacokinetic properties of 3r
and 8r were analyzed by HDBioscieces and Medicilon Companies,
Shanghai, China. Fifteen male CD-1 mice that are 5 weeks old and
have body weight of 17−20 g (Shanghai Laboratory Animal Center,
China) were used for the pharmacokinetic experiments of 3r. Six male
SD rats with body weight of 230−260 g were purchased from Shanghai
SIPPR-BK LAB Animal Ltd., Shanghai, China, and used for the
pharmacokinetic analysis of 8r. Compound 3r was dissolved/suspended
in 5% DMSO, 10% Cremophor, and 85% saline for intravenous
administration (iv) and in 5% DMSO and 95% (26% SBE-β-CD) for
oral administration (po). Compounds 28s and 8r were formulated in
10% DMSO plus 40% HP-β-CD and 5% DMSO/95% (20% HP-β-
CD) for the po and iv administrations. A final dosage of 5 mg/kg
mouse/rat of the formulated compounds was administrated, and the
blood samples were taken at various time points in 24 h. The con-
centration of the compounds in blood was analyzed by LC−MS/MS
(Shimadzu liquid chromatographic system and API4000 mass
spectrometer, Applied Biosystems, Ontario, Canada).
Solubility of PDE9A Inhibitors in Simulated Gastric/Intestinal
Fluids. The simulated gastric fluid was prepared by dissolving 1 g of
pepsin (Aladdin) into diluted hydrochloric acid, pH 1.4. The simulated
intestinal fluid was prepared by dissolving 1 g of trypsin (Aladdin) into
a solution of KH2PO4, pH 6.8. Compounds 3r, 3s, and 28s were
dissolved in acetonitrile (HPLC-grade, Honeywell Burdick & Jackson)
and mixed with the internal standard 1,3-dimethyl-5-fluorouracil
(Sigma) to generate the standard curve.
The excess compounds 3r, 3s, and 28s were incubated with the
simulated gastric/intestinal fluids (4 mL) for 24−48 h at 37 °C. After
24−48 h, the samples were passed through 0.22 μm filter (Millipore)
and then loaded to the HPLC system. HPLC experiments were
performed in a Shimadzu LC-20AT HPLC system, and wavelength of
254 nm was used for detection. A Thermo Hypersil MOS-2 C8 column
(150 mm × 4.6 mm, 5 mm) was run at 37 °C with a mobile phase of
0.1% aqueous formic acid and 0.1% formic acid acetonitrile (60:40%,
v/v) at flow rate of 1.0 mL/min. The retention time and peak area
were determined for each compound. The average peak areas from
the triplicate measurements were compared with the standard curve to
calculate the mean solubility.
Stability of 3r in the Mouse Liver Microsome. CD-1 mouse
liver microsome was purchased from BD Gentest Corporation
(Woburn, MA, USA). Compound 3r was dissolved in 100% DMSO
as 10 mM stock solution and diluted to a final concentration of 0.5 μM
for the experiments. Warfarin (Sigma, St. Louis, MO, USA), testo-
sterone (Acros, Belgium), and propranolol (TRC, Toronto, Canada)
were used as the positive controls. Liver microsome incubations
were conducted in duplicate in 96-well plates. Each well contains
30 μL of 0.1 M potassium phosphate buffer (pH 7.4), 3.0 mM MgCl2,
0.75 mg/mL mouse liver microsome, and 0.75 μM 3r or the positive
controls. After 5 min of preincubation at 37 °C, 15 μL of 3 mM
NADPH in 0.1 M potassium phosphate buffer was added to initiate
the enzymatic reaction. Reactions were terminated at various time
points (0, 5, 10, 20, 30 min) by adding 90 μL of ice-cold acetonitrile
containing internal standard. A parallel incubation was performed
using 0.1 M potassium phosphate buffer (pH 7.4) as the negative
control, and reactions were terminated after 30 min incubation.
A Shimadzu liquid chromatographic system and an API4000 mass
spectrometer equipped with Turbo Ion Spray (ESI) interface (Applied
Biosystems, Concord, Ontario, Canada) were used for detection.
Analyst 1.5 software packages (Applied Biosystems) were used for
control of the LC−MS/MS system, as well as data acquisition and
processing.
Acute Toxicity of 3r. The acute toxicity was tested following the
similar protocols described in our previous study.50 Twenty-four KM
mice (22 days, 18−20 g), purchased from the Laboratory Animal
Center of Sun Yat-Sen University (Guangzhou, China), were used to
evaluate the acute toxicity of 3r. Mice were randomly divided into
three groups, each of which was given in single oral dose of 0, 600, or
1200 mg/kg 3r on the first day of the experiment. Mice were
maintained on a 12 h light/dark cycle (light from 7:00 to 19:00) at
room temperature and 60−70% relative humidity. Sterile food and
water were given according to the institutional guidelines. Prior to each
experiment, mice were fasted overnight and allowed free access to
water. Compound 3r was dissolved in 5% DMSO and 95% (26% SBE-
β-CD) solution and orally administrated. Mice were observed for any
abnormal behavior and mortality and weighed at the fourth hour of 3r
administration and then every 24 h for 14 days. Animals were sacrificed
on the 14th day, and tissue samples of heart, liver, and kidney were
macroscopically examined for possible damages.
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